NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis $2.12 -0.05 (-2.08%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Larimar Therapeutics Stock (NASDAQ:LRMR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Larimar Therapeutics alerts:Sign Up Key Stats Today's Range$2.10▼$2.2250-Day Range$2.16▼$4.3752-Week Range$2.10▼$6.42Volume500,896 shsAverage Volume2.46 million shsMarket Capitalization$219.71 millionP/E RatioN/ADividend YieldN/APrice Target$10.33Consensus RatingBuy Company Overview Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms. Larimar is advancing nomlabofusp toward potential FDA approval. In June 2026, the company submitted the first module of its rolling Biologics License Application (BLA), seeking accelerated approval, with the remaining modules expected to be submitted in the second half of 2026. Larimar also plans to explore additional applications for its protein-delivery technology. Its shares trade on the Nasdaq under the symbol LRMR. AI Generated. May Contain Errors. Read More Larimar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreLRMR MarketRank™: 2.59702670701 of 5 starsLarimar Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 615th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLarimar Therapeutics has a consensus price target of $10.33, representing about 381.3% upside from its current price of $2.15.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Larimar Therapeutics are expected to grow in the coming year, from ($1.37) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.41% of the float of Larimar Therapeutics has been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 10.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.91 News SentimentLarimar Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Larimar Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for LRMR on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows11 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.00% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LRMR Stock News Headlines3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead (LRMR)Inventiva, Larimar Therapeutics, and Ascentage Pharma face key drug-development milestones, with analysts assigning Buy ratings and triple-digit upside price targets to all three biotech stocks.October 10, 2026 | marketbeat.comLarimar Therapeutics Names John Harlow As President And COOSeptember 30, 2026 | rttnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 14 at 1:00 AM | Porter & Company (Ad)Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating OfficerSeptember 29, 2026 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)September 29, 2026 | theglobeandmail.comLarimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in PlaySeptember 3, 2026 | tipranks.comLarimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor SpotlightAugust 21, 2026 | tipranks.comRegulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for NomlabofuspAugust 7, 2026 | theglobeandmail.comSee More Headlines LRMR Stock Analysis - Frequently Asked Questions How have LRMR shares performed this year? Larimar Therapeutics' stock was trading at $3.81 on January 1st, 2026. Since then, LRMR stock has decreased by 43.6% and is now trading at $2.1470. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.08. When did Larimar Therapeutics IPO? Larimar Therapeutics (LRMR) raised $90 million in an initial public offering on Thursday, June 19th 2014. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Larimar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Larimar Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), SoundHound AI (SOUN), Advanced Micro Devices (AMD), Rocket Lab (RKLB), Super Micro Computer (SMCI) and Archer Aviation (ACHR). Company Calendar Last Earnings8/04/2026Today10/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, LRMR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LRMR CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees71Year Founded2005Price Target and Rating Average Price Target for Larimar Therapeutics$10.33 High Price Target$14.00 Low Price Target$5.00 Potential Upside/Downside+388.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$165.67 million Net MarginsN/A Pretax MarginN/A Return on Equity-137.39% Return on Assets-97.65% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio4.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book2.25Miscellaneous Outstanding Shares103,880,000Free Float99,728,000Market Cap$219.71 million OptionableOptionable Beta0.68 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:LRMR) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
